Aspirin Demonstrates Significant Impact in Stopping Colorectal Cancer Recurrence, Trial Confirms

A daily intake of the medication can dramatically reduce the risk of certain colorectal cancers coming back after operation, as per a large-scale research into the protective impact of the common medication.

European scientists observed that individuals who consumed a low regular dose of the drug after receiving tumour surgery were 50% unlikely to have a cancerous return over the subsequent 36 months than those who were given a inactive treatment.

The trial included cancer patients whose cancers possessed particular gene changes that made them susceptible to aspirin’s tumor-inhibiting qualities. Roughly two-fifths of colorectal cancer patients display such mutations.

“In my opinion this could alter medical guidelines,” said the principal investigator. “For those with these alterations, the chance of the disease coming back was lowered by over 50%. It is a huge impact.”

Close to two million people are found to have colorectal cancer annually around the world, with over forty thousand cases in the UK. Numerous undergo tumor surgery, but in spite of improvements in chemotherapy, beam therapy and operative procedures, the cancer can return if cancerous tissue are remaining.

Rates of bowel cancer are increasing across the globe in people under 50, and while the factors are not fully understood, experts believe that junk food, excess weight, a lack of physical activity and harmful substances produced by digestive flora are contributory.

Previous research have demonstrated that this medication can help reduce colorectal cancer in people who are at elevated risk due to inherited syndromes such as Lynch syndrome. However, it was uncertain whether the medication decreased the likelihood of malignancy coming back after treatment.

Researchers recruited more than 3,500 patients who had had bowel tumour resection at hospitals across Northern Europe. Molecular tests on nearly 3,000 of the participants revealed a significant number, or 37%, had mutations in DNA that make up a molecular mechanism called PI3K, which is involved in the disease.

The individuals with the mutations were randomly assigned to use either a specific amount of aspirin each day or a dummy treatment for an extended period after surgery. Those taking aspirin were more than half less likely to see the cancer return than those on the control group, the research demonstrated.

The treatment seems to guard against the disease by reducing swelling, interfering with the PI3K mechanism, and limiting the function of clotting cells, which can surround malignant cells and thereby mask them from the patient’s defenses.

Scientists highlighted the importance to perform DNA screening on all bowel cancers so that individuals who may profit from this approach could be prescribed the therapy. “This is a common treatment that is extremely low-cost,” they noted.

This medication has been in use for longer than a hundred years, but consuming the drug regularly still carries dangers. In the study, four participants suffered “severe side effects” likely connected to the treatment, including allergy, digestive hemorrhage and bleeding on the brain. Several patients succumbed across both groups of the study, with one fatality potentially caused by the treatment.

A scientist commented: “Reducing cancer diagnoses preserves life, and finding innovative methods to accomplish this is key to our efforts to beat cancer. There is mounting data that in certain individuals of people, small-dose aspirin can offer defense from intestinal cancer.”

“It requires larger, high-quality trials to validate which patients would see the greatest advantage from consuming this drug to help them survive longer, healthier quality of life, free from the concern of the disease.”